HemoGenyx Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of a suite of products to address current problems associated with the treatment of blood disorders such as cancers and autoimmune diseases, with bone marrow, or hematopoietic stem cell, transplants, and with viral infections. The firm is engaged in the discovery, development and commercialization of a suite of products to address problems associated with the treatment of blood disorders, such as cancers and autoimmune diseases, and viral infections. Its products include immunotherapy product candidates for the treatment of acute myeloid leukemia (AML) and other blood malignancies and patient conditioning for bone marrow transplantation (the CDX bi-specific antibody and CAR-T therapy), and a cell therapy product for BM/HSC transplantation (the Hu-PHEC). Its lead product, HG-CT-1, is a CAR-T cell therapy designed to treat relapsed or refractory acute myeloid leukemia (R/R AML), which is in a Phase I clinical trial. Its Chimeric Bait Receptor (CBR) is a versatile range of potential treatments based on the methodology of programming immune cells using a type of modifiable synthetic receptor to destroy viral pathogens.
Follow-Up Questions
Who is the CEO of Hemogenyx Pharmaceuticals PLC?
Dr. Vladislav Sandler is the Chief Executive Officer of Hemogenyx Pharmaceuticals PLC, joining the firm since 2017.
What is the price performance of HOPHF stock?
The current price of HOPHF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Hemogenyx Pharmaceuticals PLC?
Hemogenyx Pharmaceuticals PLC belongs to Biotechnology industry and the sector is Health Care
What is Hemogenyx Pharmaceuticals PLC market cap?
Hemogenyx Pharmaceuticals PLC's current market cap is $0
